• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About
  • Consumer Info
  • Guideline Notes
  • Medicine and Media
  • Pharmacogenomics
  • Visit My Etsy Store

Digital PharmD

Informatics in Pharmacy

What REDUCE-IT Means to You

January 10, 2019 By Dr. G, PharmD

Print Friendly, PDF & Email

A Cochrane review in July of 2018 found no real benefit to fish oil in reducing risks of heart attack, stroke or cardiovascular risk. That challenged the conventional belief that this was one over-the-counter supplement that actually worked. However, a few recent studies have contradicted the Cochrane review and found there may be some benefit after all. How does this new data affect you and your patients?

REDUCE-IT has the most promising data on fish oil and the reduction of cardiovascular risks so far. REDUCE-IT demonstrated a statistically significant relative risk reduction of 25% in the first occurrence of major adverse cardiovascular events in individuals provided 4 grams/day of Vascepa, a prescription fish oil, compared to those receiving placebo.

The patients in REDUCE-IT were patients with high triglycerides despite already being treated with statins. It’s also of interest that Vascepa is EPA only, where most fish oils are a mixture of EPA and DHA. With the over-the-counter variety, it’s always unclear exactly what the ratio is. Even if it is stated on the label, you never know what you’re getting. Another important point is that patients in REDUCE-IT got 4 grams of Vascepa every day. Most clinicians recommend 1 gram daily.

Other recent studies have shown some benefit in combination fish oils with lower doses. The recent ASCEND study studied the effects of 1000 mg of fish oil in patients with diabetes. August 2018, showed that there were fewer vascular deaths in the EPA/DHA group than in the placebo group. The reduction in total coronary death was not significant. These results were not as promising as the REDUCE-IT trial but did show some benefit to fish oil supplementation.

VITAL studied Omacor, a prescription combination of EPA and DHA, and vitamin D. The primary endpoint in this trial was the prevention of cardiovascular events and cancer in men 50 years of age or older and in women 55 years of age or older. The primary cardiovascular event endpoint included myocardial infarction, stroke, or death from CVD.

VITAL did not find Omacor was effective for primary prevention of CV or cancer events among healthy middle-aged men and women over 5 years of follow-up. VITAL did find significant differences in some of the secondary endpoints. Omacor reduced the risk of total MI by 28% and of coronary heart disease by 17%. This was the first large-scale primary prevention trial looking at heart disease as an outcome.

What does this mean to your patients? It appears that fish oil is probably beneficial, but I’m not sure it is beneficial enough to recommend to everyone. REDUCE-IT tested a very specific population: patients with elevated triglycerides who were already being treated with a statin. As seen by the Cochrane Review and VITAL and ASCEND, the data on more diverse populations isn’t as conclusive.

Most insurances don’t cover fish oil, though that will change if evidence dictates. Currently, Vascepa costs about $311 for 120 1-gram capsules. If you’re dosing 4 capsules a day, as in REDUCE-IT, that amounts to around $10/day. There are some OTC supplements that claim to be EPA only and are made by reputable supplement manufacturers, but even those are around $30 for 60 1 gram capsules. I have a hard time recommending an intervention that is fuzzy and also costs $2-10 a day.

An interesting finding from VITAL was that African Americans and people with lower fish intake benefited more from fish oil than others. So, what I do recommend to my patients is that maybe they take an OTC fish oil supplement if it makes them feel better, but definitely eat those healthy fish that are high in EPA, like:

  • Herring
  • Salmon
  • Sturgeon fish
  • Mackerel
  • Sardines
  • Anchovies
  • Halibut
  • Rainbow trout
  • Tuna,

As an added benefit to the potential cardiovascular risk reduction, replacing a red meat meal with fish leads to an overall healthy diet. It’s always better to get it from your diet than from a supplement when possible.

Filed Under: Consumer Info, Medicine and Media

Primary Sidebar

Newsletter

More to See

What You Need to Know About the 2022 Avian Influenza Outbreak

March 20, 2022 By Dr. G, PharmD

Endocarditis Guideline Review

February 24, 2022 By Dr. G, PharmD

Sinus Troubles: When Should I See My Doctor

January 5, 2022 By Dr. G, PharmD

Tags

acid base acidosis acute coronary syndrome alkalosis analgesics anaphylaxis aortic dissection arrhythmia Beta-Blockers biostatistics blood pressure cardiac markers CHA2DS2-VasC cocaine COVID-19 diabetes diabetes inspidius Guidelines heart failure Heparin hypersensitivity hypertension hypovolemic shock intubation ionotropes journal club lipids LMWH medication safety morphine conversions myocardial infarction needs work NOAC NSTEMI obstructive shock pharmacoeconomics pheochromocytoma pressors reference materials right mi sedation septic shock shock STEMI Updated 2020

Footer

Medical Disclaimer

The medical information on this website is provided “as is” without any representations or warranties, express or implied. GoPharmD makes no representations or warranties in relation to the medical information on this website.

GoPharmD does not warrant that:

  • the medical information on this website will be constantly available, or available at all; or
  • the medical information on this website is complete, true, accurate, up-to-date, or non-misleading.
  • You must not rely on the information on this website as an alternative to medical advice from your doctor or other professional healthcare provider.
  • If you have any specific questions about any medical matter you should consult your doctor or other professional healthcare provider.

Recent

  • Smoking
  • What You Need to Know About the 2022 Avian Influenza Outbreak
  • Endocarditis Guideline Review
  • Sinus Troubles: When Should I See My Doctor
  • Common Pharmacogenomic SNPs and Interactions

Search

Tags

acid base acidosis acute coronary syndrome alkalosis analgesics anaphylaxis aortic dissection arrhythmia Beta-Blockers biostatistics blood pressure cardiac markers CHA2DS2-VasC cocaine COVID-19 diabetes diabetes inspidius Guidelines heart failure Heparin hypersensitivity hypertension hypovolemic shock intubation ionotropes journal club lipids LMWH medication safety morphine conversions myocardial infarction needs work NOAC NSTEMI obstructive shock pharmacoeconomics pheochromocytoma pressors reference materials right mi sedation septic shock shock STEMI Updated 2020